GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL is supported by a highly differentiated Galleri test with one of the largest prospective cancer-screening datasets, including ~35,000 participants in PATHFINDER 2 and ~142,000 in NHS-Galleri, which showed 99.6% specificity, >90% cancer signal origin accuracy, and a 14% reduction in Stage IV diagnoses across 12 pre-specified cancers. The clinical evidence, combined with a near-term FDA catalyst and a pathway to Medicare reimbursement following the February 2026 legislation, materially improves the company’s commercialization visibility and de-risks adoption versus earlier stages of the story. Although management still faces a long reimbursement and guideline-coverage ramp, GRAIL’s pure-play exposure to the large multi-cancer early detection market and its ability to win uptake through non-traditional channels and international markets support a favorable fundamental outlook.

GRAIL is facing a fundamentally challenging commercial ramp because revenue and test volume missed expectations, with Galleri screening revenue of about $37.3 million and volume of roughly 56,400 both below estimates, while the shortfall was concentrated in digital, employer, and consumer channels. Pricing pressure is worsening the outlook as ASP fell to about $660, management launched a September promotion, and full-year 2026 screening revenue growth guidance was cut to 17–21% from 22–32%, reinforcing concerns that the pre-reimbursement market is narrower than the Street assumed. At the same time, adjusted gross margin compressed to 42% from 55% a year ago, and with competition intensifying and reimbursement still not yet in place, the business remains loss-making and exposed to further margin and cash-burn pressure.